ArticleJournal of oncology2022

A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.

Bowen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.